Lysin (K)-specific demethylase 1 inhibition enhances proteasome inhibitor response and overcomes drug resistance in multiple myeloma.

Publikation

Lysin (K)-specific demethylase 1 inhibition enhances proteasome inhibitor response and overcomes drug resistance in multiple myeloma.

Wissenschaftlicher Artikel/Review - 10.08.2023

Bandini Cecilia, Mereu Elisabetta, Paradzik Tina, Labrador Maria, Maccagno Monica, Cumerlato Michela, Oreglia Federico, Prever Lorenzo, Manicardi Veronica, Taiana Elisa, Ronchetti Domenica, D'Agostino Mattia, Gay Francesca, Larocca Alessandra, Besse Lenka, Merlo Giorgio Roberto, Hirsch Emilio, Ciarrocchi Alessia, Inghirami Giorgio Ga, Neri Antonino, Piva Roberto

Zitation

Bandini C, Mereu E, Paradzik T, Labrador M, Maccagno M, Cumerlato M, Oreglia F, Prever L, Manicardi V, Taiana E, Ronchetti D, D'Agostino M, Gay F, Larocca A, Besse L, Merlo G, Hirsch E, Ciarrocchi A, Inghirami G, Neri A, Piva R. Lysin (K)-specific demethylase 1 inhibition enhances proteasome inhibitor response and overcomes drug resistance in multiple myeloma. Exp Hematol Oncol 2023; 12:71.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Exp Hematol Oncol 2023; 12

Veröffentlichungsdatum

10.08.2023

ISSN (Druck)

2162-3619

Seiten

Kurzbeschreibung/Zielsetzung

Multiple myeloma (MM) is an incurable plasma cell malignancy, accounting for approximately 1% of all cancers. Despite recent advances in the treatment of MM, due to the introduction of proteasome inhibitors (PIs) such as bortezomib (BTZ) and carfilzomib (CFZ), relapses and disease progression remain common. Therefore, a major challenge is the development of novel therapeutic approaches to overcome drug resistance, improve patient outcomes, and broaden PIs applicability to other pathologies.